Preferred Label : Fragile X tremor/ataxia syndrome;
Symbol : FXTAS;
CISMeF acronym : FXTAS;
Type : Phenotype, molecular basis known;
Description : Jacquemont et al. (2007) provided a review of fragile X syndrome, which they characterized
as a neurodevelopmental disorder, and FXTAS, which they characterized as a neurodegenerative
disorder. Amiri et al. (2008) provided a review of FXTAS and noted that the pathogenesis
of the disorder is distinct from that in fragile X syndrome. FXTAS results form a
toxic gain of function of FMR1 RNA, whereas fragile X syndrome results from a loss
of FMR1 function. The penetrance of FXTAS in male carriers aged 50 years and over,
ascertained through families with a fragile X syndrome proband, is at least 33% (Hagerman
and Hagerman, 2004); its penetrance in female carriers is approximately 5-10% (Greco
et al., 2008).;
Inheritance : X-linked dominant;
Molecular basis : Caused by trinucleotide repeat expansion (CGG)n in the fragile site mental retardation
gene (FMR1, 309550.0004);
Laboratory abnormalities : Increased intracellular FMRP mRNA; Decreased intracellular FMR protein;
Prefixed ID : #300623;
Origin ID : 300623;
UMLS CUI : C1839780;
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)